How big is Frequency Therapeutics, Inc.?

As of Jun 18, Frequency Therapeutics, Inc. has a market capitalization of 118.04 million and reported net sales of 4.82 million with a net profit of -87.42 million over the latest four quarters.

As of Jun 18, Frequency Therapeutics, Inc. has a market capitalization of 118.04 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 4.82 million, while the sum of net profit for the same period is -87.42 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 160.41 million and total assets of 226.24 million.

What does Frequency Therapeutics, Inc. do?

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small molecule drugs to regenerate healthy tissue. As of March 2025, it reported net sales of $3 million and a net loss of $23 million, with a market cap of $118.04 million.

Overview: Frequency Therapeutics, Inc. is a clinical-stage progenitor cell activation regeneration company in the Pharmaceuticals & Biotechnology industry, focused on developing small molecule drugs to restore healthy tissue.<BR><BR>Financial Snapshot: Most recent Net Sales: 3 Million (Quarterly Results - Mar 2025). Most recent Net Profit: -23 Million (Quarterly Results - Mar 2025). Market cap: USD 118.04 Million (Micro Cap).<BR><BR>Key Metrics: P/E: NA (Loss Making). Industry P/E: NA. Dividend Yield: 0.00%. Debt Equity: -0.81. Return on Equity: -62.91%. Price to Book: 0.85.<BR><BR>Contact Details: Address: 19 Presidential Way Ste 203, WOBURN MA: 01801-1184. Tel: ['1 781 3154600', '1 617 9140008']. Fax: 1 302 6365454. Website: http://www.frequencytx.com/.

Should I buy, sell or hold Frequency Therapeutics, Inc.?

Who are in the management team of Frequency Therapeutics, Inc.?

As of March 2022, the management team of Frequency Therapeutics, Inc. includes Lead Independent Chairman Marc Cohen, CEO David Lucchino, and several Independent Directors: Timothy Barberich, Cynthia Feldmann, Michael Huang, Robert Langer, and Joel Marcus. They are responsible for guiding the company's strategic direction and operations.

As of March 2022, the management team of Frequency Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Marc Cohen, who serves as the Lead Independent Chairman of the Board Director.<BR>- Mr. David Lucchino, who is the President, Chief Executive Officer, Co-Founder, and Director.<BR>- Mr. Timothy Barberich, who is an Independent Director.<BR>- Ms. Cynthia Feldmann, who is also an Independent Director.<BR>- Mr. Michael Huang, serving as an Independent Director.<BR>- Dr. Robert Langer, who is an Independent Director.<BR>- Mr. Joel Marcus, who is an Independent Director.<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Is Frequency Therapeutics, Inc. technically bullish or bearish?

As of June 6, 2025, the market trend is mildly bearish, indicated by mixed signals from the MACD, moving averages, Bollinger Bands, and KST, suggesting cautious optimism amid some positive momentum.

As of 6 June 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by several key indicators. The MACD is mildly bullish on both the weekly and monthly time frames, suggesting some positive momentum, but this is countered by the daily moving averages indicating a bearish trend. The Bollinger Bands and Dow Theory both reflect a mildly bearish outlook on the monthly and weekly charts. The KST shows a mixed signal with a mildly bullish weekly reading but bearish monthly. Overall, while there are some signs of potential recovery, the prevailing indicators suggest a cautious stance.

Is Frequency Therapeutics, Inc. overvalued or undervalued?

As of March 18, 2025, Frequency Therapeutics, Inc. is considered risky and overvalued due to poor financial metrics and significant underperformance compared to the S&P 500, with a year-to-date return of -12.74% and a five-year decline of 97.34%.

As of 18 March 2025, the valuation grade for Frequency Therapeutics, Inc. has moved from does not qualify to risky, indicating a deteriorating outlook. The company appears to be overvalued given its financial metrics, including a Price to Book Value of 0.98, an EV to Sales ratio of 4.99, and an ROE of -62.91%. In comparison to peers, Frequency Therapeutics has a significantly negative EV to EBITDA of -0.26, while Surrozen, Inc. shows a more favorable EV to EBITDA of -0.3289.<BR><BR>The stock has underperformed against the S&P 500, with a year-to-date return of -12.74% compared to the index's 12.22%, and over the past five years, it has declined by 97.34% while the S&P 500 gained 96.61%. This stark contrast reinforces the view that Frequency Therapeutics is currently overvalued.